EBO - EBOS Group

[System]

EBOS Group Limited (EBO) is involved in the sales, distribution and marketing of healthcare, medical, pharmaceutical and animal care products in the Australasia region.

The Company is publicly listed on the New Zealand Stock Exchange and has over 2,200 staff headquartered in New Zealand, with over 40 offices located throughout Australasia.

It is anticipated that EBOS Group will list on the ASX on November 29th, 2013.

http://www.ebos.co.nz

 

[notting]

These are the guys that picked up the 1B Chemist Wharehouse contract off SIG today.
Commencing in a years time.
Market didn't show much elation about it. Perhaps it was widely known. Got a 4.5% bounce but couldn't crack it's year high and came off to that.

 

[Dona Ferentes]

These are the guys that picked up the 1B Chemist Wharehouse contract off SIG today.
Commencing in a years time..

So, now 5 years down the track...

.
Not following the company, but what's been happening recently?

 

[Dona Ferentes]

down 10 per cent...
Sigma SIG got the CW gig.

 

[divs4ever]

hmmm ! have previously skipped skipped over EBO preferring SIC and ( the now acquired ) API

might be time to warm up the calculator and find the tape measure ( for a look at EBO )

cheers

 

[Dona Ferentes]

5Bill MC, dual-listed .

.
and ticking along, weathered the bad news of earlier this year (probably better margins with smaller players )

 

[Dona Ferentes]

Reasons for trading halt: In light of media speculation regarding EBOS and its potential interest in Greencross, a trading halt is requested until EBOS is in a position to make an announcement regarding the subject matter of the speculation.
.
tricky, buying something PE has held and likely stripped the carcass bare?

 

[Dona Ferentes]

.
adjusted to a new level after CW contract loss news
No Greencross acquisition

Outlook
EBOS is pleased with the strong earnings growth in the first half of FY24 and is successfully managing its EBITDA margin in the current environment. January 2024 trading conditions were positive with the Underlying EBITDA growth rates including and excluding the Chemist Warehouse Australia contract, consistent with the levels recorded in the first half.

The Group is confident that for the remainder of FY24 it will continue to generate organic earnings growth across both Healthcare and Animal Care and pursue further bolt-on acquisitions. We will continue to service the Chemist Warehouse Australia contract until its expiry date of 30 June 2024. Thereafter, we do not expect to generate revenue from this contract.

The Group expects to have capital expenditure in FY24 slightly above the FY23 level as we continue to invest for growth and modernise our facilities, particularly our New Zealand Healthcare operations. EBOS’ balance sheet is strong and well positioned to pursue growth opportunities.